Bavachinin

Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC50 value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity.[1][2][3][4][5].

Product Specifications

CAS Number

[19879-30-2]

Product Name Alternative

7-O-Methylbavachin; Bavachinin A

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Amyloid-β; HIF/HIF Prolyl-Hydroxylase; PPAR

Type

Natural Products

Related Pathways

Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Neuronal Signaling; Vitamin D Related/Nuclear Receptor

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/Bavachinin.html

Purity

99.95

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C1C[C@@H](C2=CC=C(O)C=C2)OC3=CC(OC)=C(C/C=C(C)\C)C=C13

Molecular Formula

C21H22O4

Molecular Weight

338.40

Precautions

H302, H315, H319, H335

References & Citations

[1]Chen X, et al. Isobavachalcone and bavachinin from Psoraleae Fructus modulate Aβ42 aggregation process through different mechanisms in vitro. FEBS Lett. 2013 Sep 17;587 (18) :2930-5.|[2]Nepal M, et al. Anti-angiogenic and anti-tumor activity of Bavachinin by targeting hypoxia-inducible factor-1α. Eur J Pharmacol. 2012 Sep 15;691 (1-3) :28-37.|[3]Chen X, et al. Treatment of allergic inflammation and hyperresponsiveness by a simple compound, Bavachinin, isolated from Chinese herbs. Cell Mol Immunol. 2013 Nov;10 (6) :497-505.|[4]Lu-Na Ge, et al. Bavachinin exhibits antitumor activity against non small cell lung cancer by targeting PPARγ. Mol Med Rep. 2019 Sep;20 (3) :2805-2811.|[5]Li Feng, et al. Bavachinin, as a novel natural pan-PPAR agonist, exhibits unique synergistic effects with synthetic PPAR-γ and PPAR-α agonists on carbohydrate and lipid metabolism in db/db and diet-induced obese mice. Diabetologia. 2016 Jun;59 (6) :1276-86.